Company Profiles

driven by the PitchBook Platform

NeuroGenetic Pharmaceuticals

NeuroGenetic Pharmaceuticals
2009 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
Series B LATEST DEAL TYPE (Upcoming)
$5M LATEST DEAL AMOUNT
3 INVESTORS
Description

Developer of drugs for the prevention of neurodegenerative conditions designed to treat Alzheimer's disease. The company's patented technology of Gamma-Secretase Modulators (GSMs) is based on an innovative modulation of a key enzyme in the amyloid pathway, called γ-secretase, enabling patients to start their treatment before the onset of dementia.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
445 Marine View Avenue
Suite 101
Del Mar, CA 92014
United States

+1 (858) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore NeuroGenetic Pharmaceuticals’s full profile, request a free trial.

NeuroGenetic Pharmaceuticals Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series B) $5M Upcoming Generating Revenue
6. Grant 10-Nov-2015 00.000 00.00 Completed Generating Revenue
5. Convertible Debt 11-Mar-2015 0000 00.00 Completed Generating Revenue
4. Convertible Debt 09-Jan-2014 00000 00.000 Completed Startup
3. Convertible Debt 25-Sep-2012 00000 00.000 Completed Startup
2. Early Stage VC (Series A) 04-Jan-2012 $2.86M $4M 00.00 Completed Startup
1. Early Stage VC (Series A) 07-Jul-2010 $1.14M $1.14M 00.000 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

NeuroGenetic Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series A 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
To view this company’s complete Cap Table, request access »

NeuroGenetic Pharmaceuticals Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
National Institute of Aging (NIA) Other 000 0000 000000 0
National Institutes of Health Government 000 0000 000000 0
AbbVie Ventures Corporate Venture Capital Minority 000 0000 000000 0

NeuroGenetic Pharmaceuticals Executive Team (6)

Name Title Board
Seat
Contact
Info
William Comer Ph.D Co-Founder, Chairman & Chief Executive Officer
Rudolph Tanzi Ph.D Co-Founder
Steven Wagner Co-Founder
Janet McClean Manager, Finance
Maria Kounnas Ph.D Senior Vice President, Research

1 Former Executive

You’re viewing 5 of 6 executives. Get the full list »

NeuroGenetic Pharmaceuticals Board Members (4)

Name Representing Role Since Contact
Info
Barry Quart Self Board Member 000 0000
Thomas Reed Self Board Member 000 0000
William Comer Ph.D NeuroGenetic Pharmaceuticals Co-Founder, Chairman & Chief Executive Officer 000 0000

1 Former Board Member

You’re viewing 3 of 4 board members. Get the full list »
Questions or concerns about this profile? Reach out to website-support@pitchbook.com